CAR-T cell technology is considered the latest achievement in cancer medicine. The first approvals in Europe took place in mid-2018 – Switzerland followed at the end of 2018. Currently, the new therapeutic approach seems to be able to achieve good results, especially against B-cell lymphoma and in acute lymphoblastic leukemia. But the research continues…